Skip to content
2000
Volume 25, Issue 11
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

There are several vaccines available for preventing various bacterial and viral infections, but still, there are many challenges that require the development of noninvasive, more efficient, and active vaccines. The advancement in biotechnological tools has provided safer antigens, such as nucleic acids, proteins etc., but due to their lower immunogenic property, adjuvants of stronger immune response are required. Nanovaccines are effective vaccines when compared with conventional vaccines as they can induce both Humoral and cell-mediated immune responses and also provide longer immunogenic memory. The nanocarriers used in vaccines act as adjuvant. They provide site-specific delivery of antigens and can be used in conjugation with immunostimulatory molecules for enhancing adjuvant therapy. The nanovaccines avoid degrading cell pathways and provide effective absorption into blood vessels. The higher potential of nanovaccines to treat various diseases, such as acquired immuno deficiency syndrome, cancer, tuberculosis, malaria and many others, along with their immunological mechanisms and different types, have been discussed in the review.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/0113892010254221231006100659
2024-08-01
2025-01-15
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/0113892010254221231006100659
Loading

  • Article Type:
    Review Article
Keyword(s): cell-mediated; humoral; immune response; infectious diseases; nanovaccine; Vaccine
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test